ArticleJournal of inflammation (London, England)2025
Erianin regulates allergic rhinitis via KAT2A-mediated histone succinylation.
Article in Journal of inflammation (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllergic rhinitis arthritis (AR) is a common chronic inflammatory disease, which may lead to other systemic chronic diseases. Erianin, a natural product isolated from Dendrobium chrysotoxum, has been reported to exert effects on a variety of diseases. In this work, we aimed to explore the effects and mechanisms of erianin in allergic rhinitis.
methodsInterleukin-13 (IL-13) was selected to treat nasal epithelial cells (NECs) to establish an in vitro AR model; Ovalbumin (OVA) was used to treat the nasal cavity of mice to establish an in vivo AR model; Cell counting kit 8 (CCK-8) was used to detect the cell activity of nasal epithelial cells after different treatments; Apoptosis and inflammatory cell infiltration of nasal tissue were analyzed by TUNEL and H&E staining, respectively; Mice noses scratching were counted to determine the severity of inflammation; Inflammation-related cytokine expression was examined by qPCR and ELISA to determine how erianin alleviates inflammation; Changes in apoptosis and histone acetylation succinylation modification were examined by Western blotting; Enrichment of KAT2A and histone succinylation at the p65 promoter was detected by ChIP-seq.
resultsErianin inhibited IL-13-induced inflammation in nasal epithelial cells in vitro, while alleviating OVA-induced rhinitis in mice in vivo. In further mechanistic studies, Erianin was found to regulate the disease through KAT2A-mediated histone succinylation. Erianin blocked KAT2A as well as H3K79 succinylation and further inhibited p65 expression, thereby controlling the further development of allergic rhinitis.
conclusionErianin alleviates and inhibits allergic rhinitis through KAT2A-mediated histone succinylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.